| Literature DB >> 32766378 |
Daniele Roberto Giacobbe1,2, Antonio Salsano3,4, Filippo Del Puente1, Ambra Miette3,4, Antonio Vena1,2, Silvia Corcione5, Michele Bartoletti6, Alessandra Mularoni7, Alberto Enrico Maraolo8, Maddalena Peghin9, Alessia Carnelutti9, Angela Raffaella Losito10, Francesca Raffaelli10, Ivan Gentile8, Beatrice Maccari11, Stefano Frisone11, Renato Pascale6, Elisa Mikus12, Alice Annalisa Medaglia7, Elena Conoscenti7, Davide Ricci4, Tommaso Lupia5, Marco Comaschi11, Maddalena Giannella6, Mario Tumbarello10, Francesco Giuseppe De Rosa5, Valerio Del Bono13, Malgorzata Mikulska1,2, Francesco Santini3,4, Matteo Bassetti1,2.
Abstract
BACKGROUND: Candida species are among the most frequent causative agents of health care-associated bloodstream infections, with mortality >40% in critically ill patients. Specific populations of critically ill patients may present peculiar risk factors related to their reason for intensive care unit admission. The primary objective of the present study was to assess the predictors of candidemia after open heart surgery.Entities:
Keywords: Candida; bloodstream infection; cardiac surgery; postoperative complications
Year: 2020 PMID: 32766378 PMCID: PMC7397829 DOI: 10.1093/ofid/ofaa233
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 3.835
Univariable and Multivariable Analyses of Factors Associated With the Development of Candidemia After Open Heart Surgery
| Univariable Analysis | Multivariable Analysisa | |||||
|---|---|---|---|---|---|---|
| Variable | No. of Cases (%) 74 (100) | No. of Controls (%) 148 (100) | Odds Ratio (95% CI) |
| Odds Ratio (95% CI) |
|
| Preoperative and peri/intraoperative variables | ||||||
| Age, median (IQR), y | 72 (64–78) | 72 (64–77) | 1.00 (0.98–1.03) | .932 | ||
| Male gender | 41 (55) | 99 (67) | 0.64 (0.37–1.11) | .113 | ||
| Diabetes mellitus | 23 (31) | 29 (20) | 1.80 (0.96–3.39) | .067 | ||
| NYHA class III/IV | 53 (72) | 40 (27) | 6.26 (3.21–12.21) | <.001 | 23.81 (5.73–98.95) | <.001 |
| Preoperative serum creatinine >200 μmol/L | 29 (39) | 42 (28) | 1.63 (0.90–2.95) | .105 | ||
| COPD | 22 (30) | 36 (24) | 1.34 (0.70–2.56) | .372 | ||
| History of immunosuppression | 1 (1) | 9 (6) | 0.20 (0.02–1.64) | .133 | ||
| Charlson Comorbidity Index, median (IQR) | 5 (3–7) | 5 (3–6) | 1.08 (0.95–1.23) | .232 | ||
| Peripheral vascular disease | 14 (19) | 27 (18) | 1.04 (0.52–2.10) | .905 | ||
| Previous stroke | 12 (16) | 8 (5) | 4.00 (1.38–11.57) | .010 | 4.61 (0.68–31.28) | .118 |
| Previous IMA | 13 (18) | 31 (21) | 0.83 (0.42–1.62) | .577 | ||
| LVEF, median (IQR), % | 50 (37–55) | 55 (45–55) | 0.97 (0.95–1.00) | .031 | - | .633 |
| EuroSCORE II | 6.61 (3.67–16.43) | 3.51 (1.86–8.37) | 1.06 (1.02–1.10) | .001 | - | .177 |
| Preoperative MV | 16 (22) | 9 (6) | 3.56 (1.57–8.05) | .002 | - | .275 |
| Type of surgery | .073 | |||||
| Isolated coronary artery bypass surgery | 6 (8) | 22 (15) | (ref) | |||
| Isolated valvular surgery | 32 (43) | 48 (32) | 2.43 (0.88–6.71) | |||
| Surgery of thoracic aorta | 26 (35) | 41 (28) | 2.13 (0.78–5.82) | |||
| Other/combined procedures | 10 (14) | 37 (25) | 0.93 (0.29–2.97) | |||
| Pacemaker implantation | 2 (3) | 10 (7) | 0.40 (0.09–1.83) | .237 | ||
| CPB time, median (IQR), min | 136 (98–208) | 136 (92–197) | 1.00 (1.00-1.00) | .843 | ||
| Aortic cross-clamp time, median (IQR), min | 75 (49–120) | 87 (58–120) | 1.00 (0.99–1.00) | .127 | ||
| SOFA score at time of surgery, median (IQR) | 4 (1–7) | 3 (0–4) | 1.19 (1.07–1.34) | .002 | 1.20 (0.99–1.45) | .058 |
| Need for peri/intraoperative blood transfusion | 61 (82) | 124 (84) | 0.85 (0.33–2.22) | .854 | ||
| Need for >5 peri/intraoperative blood transfusions | 47 (64) | 86 (58) | 1.56 (0.69–3.52) | .288 | ||
| Postoperative (during time at risk) | ||||||
| Central venous catheter >48 h | 74 (100) | 141 (95) | (model not converging) | - | ||
| Total parenteral nutrition >48 h | 42 (57) | 86 (58) | 0.94 (0.50–1.74) | .833 | ||
| Hemodialysis >48 h | 27 (37) | 28 (19) | 2.55 (1.32–4.91) | .005 | - | .566 |
| Therapy with cephalosporins >48 h | 18 (24) | 12 (8) | 4.65 (1.81–11.94) | .001 | - | - |
| Therapy with carbapenems >48 h | 52 (70) | 51 (35) | 4.49 (2.37–8.49) | <.001 | 8.87 (2.57–30.67) | .001 |
| Therapy with fluoroquinolones >48 h | 49 (66) | 51 (35) | 5.78 (2.64–12.65) | <.001 | 5.73 (1.61–20.41) | .007 |
|
| 29 (39) | 45 (30) | 1.52 (0.83–2.80) | .178 | ||
|
| 19 (26) | 14 (10) | 2.95 (1.43–6.12) | .004 | - | .723 |
| Bacterial BSIb | 23 (31) | 38 (26) | 1.30 (0.69–2.47) | .415 | ||
Results are presented as No. (%) unless otherwise indicated.
Abbreviations: BSI, bloodstream infection; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; IMA, acute myocardial infarction; IQR, interquartile range; LVEF, left ventricular ejection fraction; MV, mechanical ventilation; NYHA, New York Hearth Association.
aOdds ratio and 95% CI are presented only for variables retained in the final multivariable model (ie, NYHA class III/IV, previous stroke, SOFA score at time of surgery, therapy with fluoroquinolones >48 hours, therapy with carbapenems >48 hours).
bCoagulase-negative staphylococci (n = 24), Klebsiella spp. (n = 8), Staphylococcus aureus (n = 6), Enterobacter spp. (n = 3), Pseudomonas spp. (n = 3), Enterococcus spp. (n = 2), and other bacteria with lower frequencies (n = 15).
Univariable and Multivariable Analyses of Factors Associated With 30-Day Mortality in Open Heart Surgery Patients With Postoperative Candidemia
| Univariable Analysis | Multivariable Analysisb | |||||
|---|---|---|---|---|---|---|
| Variable | Nonsurvivors, No. (%) 39 (100) | Survivors, No. (%) 35 (100) | Odds Ratio (95% CI) |
| Odds Ratio (95% CI) |
|
| Preoperative and peri/intraoperative variables | ||||||
| Age, median (IQR), y | 75 (67–79) | 68 (60–76) | 1.03 (0.99–1.08) | .129 | ||
| Male gender | 21 (54) | 20 (57) | 0.88 (0.35–2.19) | .776 | ||
| Diabetes mellitus | 11 (28) | 12 (34) | 0.75 (0.28–2.02) | .573 | ||
| NYHA class III/IV | 29 (74) | 24 (69) | 1.33 (0.48–3.66) | .582 | ||
| Preoperative serum creatinine >200 μmol/L | 17 (44) | 12 (34) | 1.48 (0.58–3.80) | .414 | ||
| COPD | 12 (31) | 10 (29) | 1.11 (0.41–3.02) | .836 | ||
| History of immunosuppression | 1 (3) | 0 (0) | (model not converging) | - | ||
| Charlson Comorbidity Index, median (IQR) | 5 (3–7) | 5 (2–6) | 1.09 (0.90–1.32) | .390 | ||
| Peripheral vascular disease | 7 (18) | 7 (20) | 0.88 (0.27–2.80) | .822 | ||
| Previous stroke | 7 (18) | 5 (14) | 1.31 (0.38–4.59) | .670 | ||
| Previous IMA | 10 (26) | 3 (9) | 3.68 (0.92–14.69) | .065 | ||
| LVEF, median (IQR), % | 50 (35–55) | 48 (39–55) | 1.00 (0.96–1.04) | .984 | ||
| EuroSCORE II | 13.57 (4.07–21.93) | 4.57 (3.43–10.34) | 1.05 (1.00–1.10) | .052 | ||
| Preoperative MV | 10 (26) | 6 (17) | 1.67 (0.54–5.19) | .378 | ||
| Type of surgery | .898 | |||||
| Isolated coronary artery bypass surgery | 4 (10) | 2 (6) | (ref) | |||
| Isolated valvular surgery | 16 (41) | 16 (46) | 0.50 (0.08–3.13) | |||
| Surgery of thoracic aorta | 14 (36) | 12 (34) | 0.58 (0.09–3.76) | |||
| Other/combined procedures | 5 (13) | 5 (14) | 0.50 (0.06–4.09) | |||
| Pacemaker implantation | 1 (3) | 1 (3) | 0.90 (0.05–14.86) | .938 | ||
| CPB time, median (IQR), min | 136 (98–198) | 137 (93–213) | 1.00 (1.00-1.00) | .652 | ||
| Aortic cross-clamp time, median (IQR), min | 73 (51–110) | 89 (49–140) | 1.00 (0.99–1.01) | .603 | ||
| SOFA score at time of surgery, median (IQR) | 4 (1–7) | 3 (1–6) | 1.02 (0.89–1.17) | .749 | ||
| Need for peri/intraoperative blood transfusion | 32 (82) | 29 (83) | 0.95 (0.29–3.14) | .928 | ||
| Need for >5 peri/intraoperative blood transfusions | 29 (74) | 18 (51) | 2.74 (1.03–7.28) | .043 | - | .151 |
| Postoperative variables (during time at risk) | ||||||
| Central venous catheter >48 h | 39 (100) | 35 (100) | - | - | ||
| Total parenteral nutrition >48 h | 25 (64) | 17 (49) | 1.89 (0.75–4.80) | .180 | ||
| Hemodialysis >48 h | 16 (41) | 11 (31) | 1.52 (0.58–3.95) | .393 | ||
| Therapy with cephalosporins >48 h | 10 (26) | 8 (23) | 1.16 (0.40–3.38) | .781 | ||
| Therapy with carbapenems >48 h | 26 (67) | 26 (74) | 0.69 (0.25–1.90) | .475 | ||
| Therapy with fluoroquinolones >48 h | 30 (77) | 19 (54) | 2.81 (1.03–7.62) | .043 | - | .115 |
|
| 13 (33) | 16 (46) | 0.59 (0.23–1.52) | .278 | ||
|
| 9 (23) | 10 (29) | 0.75 (0.26–2.13) | .590 | ||
| Bacterial BSIb | 9 (23) | 14 (40) | 0.45 (0.17–1.23) | .120 | ||
| Candidemia-related variables | ||||||
| Septic shock | 21 (54) | 6 (17) | 5.64 (1.91–16.63) | .002 | 5.64 (1.91–16.63) | .002 |
| Causative | .184 | |||||
| | 28 (74) | 20 (59) | (ref) | |||
| Non- | 10 (26) | 14 (41) | 0.51 (0.19–1.38) | |||
| Early antifungal therapy (within 48 hd) | 13 (33) | 16 (46) | 0.59 (0.23–1.52) | .278 | ||
| Early CVC removal (within 48 hd) | 13 (33) | 14 (40) | 0.75 (0.29–1.94) | .552 | ||
Results are presented as No. (%) unless otherwise indicated.
Abbreviations: BSI, bloodstream infection; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; CVC, central venous catheter; IMA, acute myocardial infarction; IQR, interquartile range; LVEF, left ventricular ejection fraction; MV, mechanical ventilation; NYHA, New York Hearth Association.
aOdds ratio and 95% CI are presented only for the variables retained in the final multivariable model (ie, septic shock).
bCoagulase-negative staphylococci (n = 8), Klebsiella spp. (n = 5), Pseudomonas spp. (n = 3), Staphylococcus aureus (n = 2), other bacteria with lower frequencies (n = 5).
cTwo nontyped species were not included in the comparison albicans vs non-albicans species. Typed non-albicans species were as follows: C. parapsilosis (n = 10), C. glabrata (n = 7), C. tropicalis (n = 3), C. krusei (n = 2), C. dubliniensis (n = 1), C. sake (n = 1).
dAfter the onset of candidemia (ie, the day when the first positive blood culture for Candida spp. was drawn).